semaglutide con b12 / Cyanocobalamin Injection Semaglutide / Cyanocobalamin Injection |

The 2nd GLP-1-Based Therapeutics Summit returns to tackle the challenges in best-in-class GLP-1 development and indication expansion with new clinical data, new preclinical data, and 18+ expert speakers including Eli Lily, Regeneron, Roche, Novo Nordisk, Fractyl Health and more at the forefront of the field

Pharmacy shop shelves in background

In participants with obesity and chronic kidney disease without diabetes, once-weekly administration of semaglutide 2.4mg led to a reduction in albuminuria, body weight and systolic blood pressure compared with placebo, with no changes to creatinine or cystatin-C estimated glomerular filtration rate or measured glomerular filtration rate during the 24-week follow-up period.

Originally developed to manage type 2 diabetes, these tablets have shown potential in helping those who are struggling with weight management

For example, semaglutide and empagliflozin showed no significant difference in 3-point MACE (HR 1.05